8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 17, 2026·SEC
Gossamer Bio, Inc.(GOSS)Earnings, Financials & Key Ratios
GOSS•NASDAQ
Price updated Jun 11, 2026
AboutGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Show more
- Revenue$48M-57.7%
- EBITDA-$162M-190.9%
- Net Income-$170M-201.4%
- EPS (Diluted)-0.75-200.0%
- Gross Margin97.93%-2.1%
- EBITDA Margin-334.74%-588.5%
- Operating Margin-336.81%-544.7%
- Net Margin-351.49%-613.2%
- ROIC-107.51%-413.7%
- Interest Coverage-14.86-287.8%
GOSS Key Insights
Gossamer Bio, Inc. (GOSS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 0/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GOSS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GOSS Price & Volume
Gossamer Bio, Inc. (GOSS) stock price & volume — 10-year historical chart
Loading chart...
GOSS Growth Metrics
Gossamer Bio, Inc. (GOSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-55.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-252.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-229.17%
Return on Capital
10 Years-70.8%
5 Years-64.28%
3 Years-61.57%
Last Year-86.13%
GOSS Recent Earnings
Gossamer Bio, Inc. (GOSS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 8/12 qtrs (89%)
Q2 2026Latest
May 18, 2026EPS
$0.20
Est $0.17
-17.6%
Revenue
$17M
Est $5M
+263.2%
Q2 2026
May 15, 2026EPS
$0.20
Est $0.17
-17.6%
Revenue
$17M
Est $5M
+263.2%
Q2 2026
Mar 17, 2026EPS
$0.21
Est $0.20
-5.0%
Revenue
$14M
Est $8M
+83.4%
Q4 2025
Nov 5, 2025EPS
$0.21
Est $0.19
-10.5%
Revenue
$13M
Est $8M
+76.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.20vs $0.17-17.6% | $17Mvs $5M+263.2% |
| Q2 2026 | May 15, 2026 | $0.20vs $0.17-17.6% | $17Mvs $5M+263.2% |
| Q2 2026 | Mar 17, 2026 | $0.21vs $0.20-5.0% | $14Mvs $8M+83.4% |
| Q4 2025 | Nov 5, 2025 | $0.21vs $0.19-10.5% | $13Mvs $8M+76.6% |
Based on last 12 quarters of dataView full earnings history →
GOSS Peer Comparison
Gossamer Bio, Inc. (GOSS) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 10.48B | 74.41 | -6099.18 | 232.58% | -48.38% | -55.09% | 0.73 | |
 MNKD | 1.16B | 3.75 | 187.50 | 22.23% | -6.63% | |||
 AVXL | 231.68M | 2.50 | -4.63 | -38.76% | ||||
 KALA | 54.17M | 2.47 | -0.75 | -13.36% | ||||
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 UTHR | 23.15B | 545.40 | 19.58 | 10.61% | 40.61% | 19.24% | ||
 LGND | 5.1B | 254.57 | 41.53 | 60.4% | 55.95% | 16.19% | 0.44 | |
 IDYA | 2.53B | 28.84 | -22.53 | 30.24% | -62.17% | -13.96% | 0.03 |
Compare GOSS vs Peers
Gossamer Bio, Inc. (GOSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GOSS Income Statement
Gossamer Bio, Inc. (GOSS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 114.7M | 48.47M | 55.54M |
Revenue Growth % | - | - | - | - | - | - | - | - | -57.74% | -55.42% |
Cost of Goods Sold | 0 | 297K | 3.09M | 4.27M | 0 | 0 | 0 | 0 | 1M | 232K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 2.07% | - |
Gross Profit | 0▲ 0% | -297K▲ 0% | -3.09M▼ 940.1% | -4.27M▼ 38.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 114.7M▲ 0% | 47.47M▼ 58.6% | 55.3M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | 100% | 97.93% | 99.58% |
Gross Profit Growth % | - | - | -940.07% | -38.17% | 100% | - | - | - | -58.61% | - |
Operating Expenses | 1.15M | 99.33M | 182.54M | 206.31M | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M | 234.09M |
OpEx % of Revenue | - | - | - | - | - | - | - | 152.24% | 434.74% | - |
Selling, General & Admin | 262K | 44.05M | 39.14M | 48.32M | 45.78M | 47.61M | 38.45M | 36.13M | 37.63M | 47.72M |
SG&A % of Revenue | - | - | - | - | - | - | - | 31.5% | 77.64% | - |
Research & Development | 891K | 55.28M | 143.4M | 158M | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M | 186.6M |
R&D % of Revenue | - | - | - | - | - | - | - | 120.74% | 359.17% | - |
Other Operating Expenses | 0 | 316K | 5.83M | 0 | 75K | 65K | 10M | 0 | -1M | -227K |
Operating Income | -6.65M▲ 0% | -148.99M▼ 2139.5% | -186.14M▼ 24.9% | -210.58M▼ 13.1% | -216.12M▼ 2.6% | -218.59M▼ 1.1% | -183.76M▲ 15.9% | -59.92M▲ 67.4% | -163.25M▼ 172.5% | -178.78M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | -52.24% | -336.81% | -321.92% |
Operating Income Growth % | -7915.66% | -2139.49% | -24.93% | -13.13% | -2.63% | -1.14% | 15.94% | 67.39% | -172.46% | - |
EBITDA | -5.5M | -148.7M | -183.05M | -206.31M | -210.96M | -214.16M | -179.37M | -55.77M | -162.25M | -178.11M |
EBITDA Margin % | - | - | - | - | - | - | - | -48.62% | -334.74% | -320.7% |
EBITDA Growth % | - | -2603.56% | -23.1% | -12.71% | -2.25% | -1.52% | 16.24% | 68.91% | -190.94% | -247.44% |
D&A (Non-Cash Add-back) | 1.15M | 297K | 3.09M | 4.27M | 5.17M | 4.43M | 4.38M | 4.15M | 1M | 678K |
EBIT | -6.65M | -146.96M | -182.54M | -230.69M | -214.56M | -215.5M | -166.31M | -44.12M | -163.25M | -170.44M |
Net Interest Income | 0 | 1.71M | 0 | -9.22M | -18.68M | -12.3M | -11.51M | -9.74M | -9.02M | -8.97M |
Interest Income | 0 | 1.72M | 0 | 3.44M | 761K | 1.58M | 2M | 1.78M | 1.97M | 2.03M |
Interest Expense | 118K | 12K | 0 | 12.67M | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M | 11M |
Other Income/Expense | -118K | 2.02M | 5.83M | -32.78M | -17.88M | -10.79M | 3.94M | 4.28M | -7.21M | -1.7M |
Pretax Income | -6.77M▲ 0% | -146.97M▼ 2070.6% | -180.31M▼ 22.7% | -243.36M▼ 35.0% | -234M▲ 3.8% | -229.38M▲ 2.0% | -179.82M▲ 21.6% | -55.63M▲ 69.1% | -170.46M▼ 206.4% | -180.48M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | -48.5% | -351.67% | -324.98% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 893K | -88K | -88K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -1.61% | 0.05% | 0.05% |
Net Income | -6.77M▲ 0% | -146.97M▼ 2070.6% | -180.82M▼ 23.0% | -243.36M▼ 34.6% | -234M▲ 3.8% | -229.38M▲ 2.0% | -179.82M▲ 21.6% | -56.53M▲ 68.6% | -170.37M▼ 201.4% | -180.4M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | -49.28% | -351.49% | -324.82% |
Net Income Growth % | -8057.83% | -2070.57% | -23.03% | -34.59% | 3.84% | 1.98% | 21.61% | 68.56% | -201.39% | -252.07% |
Net Income (Continuing) | -6.77M | -146.97M | -180.31M | -243.36M | -234M | -229.38M | -179.82M | -56.53M | -170.37M | -180.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.27▲ 0% | -2.43▼ 800.0% | -3.30▼ 35.8% | -3.67▼ 11.2% | -3.33▲ 9.3% | -2.84▲ 14.7% | -1.18▲ 58.5% | -0.25▲ 78.8% | -0.75▼ 200.0% | -0.77▲ 0% |
EPS Growth % | - | -800% | -35.8% | -11.21% | 9.26% | 14.71% | 58.45% | 78.81% | -200% | -229.17% |
EPS (Basic) | -0.27 | -2.43 | -3.30 | -3.67 | -3.33 | -2.84 | -0.80 | -0.25 | -0.75 | - |
Diluted Shares Outstanding | 24.83M | 60.4M | 54.74M | 68.51M | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M | 234.14M |
Basic Shares Outstanding | 24.83M | 60.4M | 54.74M | 68.51M | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M | 234.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GOSS Balance Sheet
Gossamer Bio, Inc. (GOSS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 445K | 231.95M | 409.32M | 522.32M | 331.78M | 261.88M | 306.52M | 309.89M | 167.64M | 124.54M |
Cash & Short-Term Investments | 315K | 228.66M | 401.77M | 512.63M | 325.22M | 255.68M | 296.43M | 294.52M | 136.93M | 99.22M |
Cash Only | 315K | 105.22M | 135.03M | 486.06M | 183.4M | 111.97M | 32.11M | 46.07M | 37.73M | 41.03M |
Short-Term Investments | 0 | 123.44M | 266.74M | 26.57M | 141.81M | 143.71M | 264.32M | 248.44M | 99.2M | 58.19M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.34M | 12.53M | 9.35M |
Days Sales Outstanding | - | - | - | - | - | - | - | 16.99 | 94.33 | 64.9 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 700K | 63K | 565K | 64K | 0 | 10.09M | 10.03M | 18.18M | 15.97M |
Total Non-Current Assets | 0 | 7.47M | 17.29M | 17.11M | 11.88M | 10.57M | 5.4M | 5.4M | 4.61M | 4.36M |
Property, Plant & Equipment | 0 | 3.19M | 15.73M | 16.08M | 10.8M | 9.89M | 4.78M | 5.12M | 4.2M | 3.96M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 22.40x | 11.55x | 12.89x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 4.27M | 1.56M | 1.03M | 1.08M | 680K | 618K | 283K | 408K | 398K |
Total Assets | 445K▲ 0% | 239.42M▲ 53702.0% | 426.6M▲ 78.2% | 539.43M▲ 26.4% | 343.66M▼ 36.3% | 272.45M▼ 20.7% | 311.92M▲ 14.5% | 315.29M▲ 1.1% | 172.25M▼ 45.4% | 128.9M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.36x | 0.28x | 0.30x |
Asset Growth % | 641.67% | 53702.02% | 78.18% | 26.45% | -36.29% | -20.72% | 14.49% | 1.08% | -45.37% | -175.4% |
Total Current Liabilities | 1.27M | 20.4M | 36.92M | 38.65M | 39.86M | 49.23M | 51.6M | 45.01M | 63.44M | 56.51M |
Accounts Payable | 97K | 2.18M | 956K | 7.51M | 3.24M | 1.46M | 5.53M | 2.32M | 5.96M | 10.82M |
Days Payables Outstanding | - | 2.68K | 112.96 | 642.09 | - | - | - | - | 2.17K | 7.78K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 11.61M | 11.61M | 0 | 938K | 957K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.05M | 0 | 56.19M |
Other Current Liabilities | 0 | 0 | 9.28M | 12.19M | 11.92M | 13.53M | 10.29M | 0 | 56.53M | 23.33M |
Current Ratio | 0.35x | 11.37x | 11.09x | 13.51x | 8.32x | 5.32x | 5.94x | 6.88x | 2.64x | 2.20x |
Quick Ratio | 0.35x | 11.37x | 11.09x | 13.51x | 8.32x | 5.32x | 5.94x | 6.88x | 2.64x | 2.20x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -7.71K |
Total Non-Current Liabilities | 6.04M | 339.08M | 37.2M | 180.1M | 182.34M | 211.14M | 197.55M | 240.79M | 231.57M | 233.88M |
Long-Term Debt | 6.04M | 0 | 28.46M | 172.39M | 179.12M | 207.7M | 197.41M | 197.52M | 198.51M | 198.76M |
Capital Lease Obligations | 0 | 0 | 8.74M | 7.71M | 3.22M | 3.45M | 144K | 4.4M | 3.46M | 10.85M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1K | 339.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7.31M | 359.49M | 74.12M | 218.75M | 222.19M | 260.37M | 249.15M | 285.8M | 295.01M | 290.38M |
Total Debt | 6.04M | 0 | 39.55M | 183.73M | 185.24M | 225.74M | 212.46M | 202.88M | 201.97M | 202.93M |
Net Debt | 5.72M | -105.22M | -95.48M | -302.32M | 1.83M | 113.77M | 180.35M | 156.81M | 164.24M | 161.91M |
Debt / Equity | - | - | 0.11x | 0.57x | 1.53x | 18.69x | 3.38x | 6.88x | - | -1.26x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.14x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.91x |
Interest Coverage | -56.38x | -12246.42x | - | -18.21x | -11.04x | -15.53x | -12.31x | -3.83x | -14.86x | -15.50x |
Total Equity | -6.86M▲ 0% | -120.07M▼ 1649.8% | 352.49M▲ 393.6% | 320.68M▼ 9.0% | 121.46M▼ 62.1% | 12.08M▼ 90.1% | 62.77M▲ 419.7% | 29.49M▼ 53.0% | -122.76M▼ 516.2% | -161.48M▲ 0% |
Equity Growth % | -5478.86% | -1649.77% | 393.57% | -9.02% | -62.12% | -90.06% | 419.74% | -53.02% | -516.25% | -3408.61% |
Book Value per Share | -0.28 | -1.99 | 6.44 | 4.68 | 1.62 | 0.14 | 0.28 | 0.13 | -0.54 | -0.69 |
Total Shareholders' Equity | -6.86M | -120.07M | 352.49M | 320.68M | 121.46M | 12.08M | 62.77M | 29.49M | -122.76M | -161.48M |
Common Stock | 0 | 2K | 7K | 8K | 8K | 10K | 23K | 23K | 24K | 24K |
Retained Earnings | -6.89M | -153.86M | -334.17M | -577.53M | -811.53M | -1.03B | -1.21B | -1.27B | -1.44B | -1.49B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -61K | 258K | 599K | 45K | -574K | -350K | 1.19M | -5.15M | -4.02M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOSS Cash Flow Statement
Gossamer Bio, Inc. (GOSS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.75M | -51.04M | -144.83M | -176.36M | -188.89M | -187.03M | -159.16M | -3.47M | -171.27M | -170.26M |
Operating CF Margin % | - | - | - | - | - | - | - | -3.02% | -353.34% | - |
Operating CF Growth % | -28825% | -788.49% | -183.74% | -21.77% | -7.1% | 0.98% | 14.9% | 97.82% | -4838.47% | -187% |
Net Income | -6.77M | -146.97M | -180.31M | -243.36M | -234M | -229.38M | -179.82M | -56.53M | -170.37M | -180.4M |
Depreciation & Amortization | 0 | 297K | 3.09M | 4.27M | 5.17M | 4.43M | 4.38M | 4.15M | 1M | 892K |
Stock-Based Compensation | 32K | 30.95M | 20.82M | 38.75M | 32.01M | 42.55M | 28.52M | 20.62M | 10.55M | 14.45M |
Deferred Taxes | 0 | 0 | 0 | -158K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 32K | 49.66M | 1.45M | 27.24M | 7.17M | -177K | 2.6M | -11.17M | 1.18M | 3.2M |
Working Capital Changes | 994K | 15.02M | 10.12M | -3.1M | 774K | -4.46M | -14.84M | 39.46M | -13.63M | -8.41M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.34M | -6.89M | -2.67M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 57K | 2.08M | -1.4M | 6.98M | -4.43M | -1.81M | 3.99M | -1.66M | -2.75M | 4.35M |
Cash from Investing | 0 | -144.71M | -147.14M | 215.34M | -117.43M | -1.03M | -110.97M | 29.02M | 156.36M | 175.9M |
Capital Expenditures | 0 | -21.21M | -2.97M | -24.88M | -1.55M | -475K | 0 | 0 | -79K | -53K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | 0.16% | 0.1% |
Acquisitions | 0 | -17.72M | 0 | 23.38M | 0 | -65K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 17.72M | -3.6M | -23.38M | -75K | 65K | 0 | 0 | 0 | 0 |
Cash from Financing | 6M | 300.86M | 321.58M | 312.54M | 3.33M | 117.09M | 190.15M | -11.49M | 6.42M | 6.43M |
Debt Issued (Net) | 6M | -40K | 28.22M | 193.6M | 0 | -5.81M | -11.61M | -12.58M | 0 | 0 |
Equity Issued (Net) | 0 | 303.04M | 291.31M | 117.11M | 0 | 119.95M | 201.32M | 1.09M | 6.42M | 6.43M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 629K | 0 | 0 |
Other Financing | 0 | -2.14M | 2.04M | 1.83M | 3.33M | 2.95M | 444K | 0 | 0 | 0 |
Net Change in Cash | 255K▲ 0% | 105.1M▲ 41117.3% | 29.67M▼ 71.8% | 351.53M▲ 1084.8% | -303.15M▼ 186.2% | -71.49M▲ 76.4% | -79.86M▼ 11.7% | 13.96M▲ 117.5% | -8.34M▼ 159.7% | 12.01M▲ 0% |
Free Cash Flow | -5.75M▲ 0% | -72.25M▼ 1157.7% | -151.4M▼ 109.5% | -201.24M▼ 32.9% | -190.51M▲ 5.3% | -187.51M▲ 1.6% | -159.16M▲ 15.1% | -3.47M▲ 97.8% | -171.34M▼ 4840.7% | -170.32M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | -3.02% | -353.5% | -306.67% |
FCF Growth % | -28825% | -1157.7% | -109.54% | -32.92% | 5.33% | 1.58% | 15.12% | 97.82% | -4840.74% | -514.22% |
FCF per Share | -0.23 | -1.20 | -2.77 | -2.94 | -2.55 | -2.22 | -0.71 | -0.02 | -0.75 | -0.73 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.35x | 0.80x | 0.72x | 0.81x | 0.82x | 0.89x | 0.06x | 1.01x | 0.94x |
Interest Paid | 0 | 0 | 1.48M | 0 | 12.74M | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOSS Key Ratios
Gossamer Bio, Inc. (GOSS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -155.6% | -72.3% | -105.85% | -343.53% | -480.5% | -122.54% | - | 174.85% |
| Return on Invested Capital (ROIC) | - | - | -880.2% | -114.71% | -228.85% | -131.61% | -74.71% | -20.93% | -107.51% | -188.91% |
| Gross Margin | - | - | - | - | - | - | - | 100% | 97.93% | 99.58% |
| Net Margin | - | - | - | - | - | - | - | -49.28% | -351.49% | -324.82% |
| Debt / Equity | - | - | 0.11x | 0.57x | 1.53x | 18.69x | 3.38x | 6.88x | - | -1.26x |
| Interest Coverage | -56.38x | -12246.42x | - | -18.21x | -11.04x | -15.53x | -12.31x | -3.83x | -14.86x | -15.50x |
| FCF Conversion | 0.85x | 0.35x | 0.80x | 0.72x | 0.81x | 0.82x | 0.89x | 0.06x | 1.01x | 0.94x |
| Revenue Growth | - | - | - | - | - | - | - | - | -57.74% | -55.42% |
Related:GOSS Dividend History·GOSS Revenue History·GOSS Price History·GOSS P/E History·GOSS Financial Ratios·GOSS Institutional Holders
GOSS SEC Filings & Documents
Gossamer Bio, Inc. (GOSS) SEC filings — annual & quarterly reports (10-K, 10-Q)
GOSS Frequently Asked Questions
Gossamer Bio, Inc. (GOSS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gossamer Bio, Inc. (GOSS) reported $55.5M in revenue for fiscal year 2025.
Gossamer Bio, Inc. (GOSS) saw revenue decline by 57.7% over the past year.
Gossamer Bio, Inc. (GOSS) reported a net loss of $180.4M for fiscal year 2025.
Dividend & Returns
Gossamer Bio, Inc. (GOSS) had negative free cash flow of $170.3M in fiscal year 2025, likely due to heavy capital investments.